Drug discovery beyond the 'rule-of-five'.

[1]  Janice M. Reichert,et al.  Development trends for monoclonal antibody cancer therapeutics , 2007, Nature Reviews Drug Discovery.

[2]  P. Hajduk,et al.  A decade of fragment-based drug design: strategic advances and lessons learned , 2007, Nature Reviews Drug Discovery.

[3]  R. Fonseca,et al.  Targeted therapeutics for multiple myeloma: The arrival of a risk-stratified approach , 2007, Molecular Cancer Therapeutics.

[4]  D. Newman,et al.  Natural products as sources of new drugs over the last 25 years. , 2007, Journal of natural products.

[5]  Joanna Owens.  2006 drug approvals: finding the niche , 2007, Nature Reviews Drug Discovery.

[6]  Mary K Joseph,et al.  Studies leading to potent, dual inhibitors of Bcl-2 and Bcl-xL. , 2007, Journal of medicinal chemistry.

[7]  S. Frantz.  Pharma faces major challenges after a year of failures and heated battles , 2007, Nature Reviews Drug Discovery.

[8]  Gisbert Schneider,et al.  Properties and Architecture of Drugs and Natural Products Revisited , 2007 .

[9]  John P. Overington,et al.  How many drug targets are there? , 2006, Nature Reviews Drug Discovery.

[10]  Stefan Wetzel,et al.  Protein structure similarity clustering: dynamic treatment of PDB structures facilitates clustering. , 2006, Angewandte Chemie.

[11]  M. Gregory,et al.  Separation of anti-angiogenic and cytotoxic activities of borrelidin by modification at the C17 side chain. , 2006, Bioorganic & medicinal chemistry letters.

[12]  A. Schwienhorst.  Direct thrombin inhibitors – a survey of recent developments , 2006, Cellular and Molecular Life Sciences CMLS.

[13]  Christine J. Martin,et al.  Rapamycin biosynthesis: Elucidation of gene product function. , 2006, Organic & biomolecular chemistry.

[14]  Ben Shen,et al.  Progress in combinatorial biosynthesis for drug discovery. , 2006, Drug discovery today. Technologies.

[15]  J. Baselga,et al.  Targeting Tyrosine Kinases in Cancer: The Second Wave , 2006, Science.

[16]  A. Debnath.  Progress in identifying peptides and small-molecule inhibitors targeted to gp41 of HIV-1 , 2006, Expert opinion on investigational drugs.

[17]  M. Gregory,et al.  Brain-selective mTOR inhibitors as potential therapeutics for glioblastoma multiforme , 2006 .

[18]  David S. Wishart,et al.  DrugBank: a comprehensive resource for in silico drug discovery and exploration , 2005, Nucleic Acids Res..

[19]  M. Hidalgo,et al.  Targeting mTOR for cancer treatment. , 2006, Current opinion in investigational drugs.

[20]  A. Schuffenhauer,et al.  Charting biologically relevant chemical space: a structural classification of natural products (SCONP). , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[21]  Ian Paterson,et al.  The Renaissance of Natural Products as Drug Candidates , 2005, Science.

[22]  M. Gregory,et al.  Mutasynthesis of rapamycin analogues through the manipulation of a gene governing starter unit biosynthesis. , 2005, Angewandte Chemie.

[23]  E. Poveda,et al.  Enfuvirtide, the first fusion inhibitor to treat HIV infection. , 2005, AIDS reviews.

[24]  A. Pavlou,et al.  The therapeutic antibodies market to 2008. , 2005, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[25]  J. T. Metz,et al.  Ligand efficiency indices as guideposts for drug discovery. , 2005, Drug discovery today.

[26]  Yaoquan Liu,et al.  Synthesis and biological activities of novel 17-aminogeldanamycin derivatives. , 2004, Bioorganic & medicinal chemistry.

[27]  Christine J. Martin,et al.  Loss of co-linearity by modular polyketide synthases: a mechanism for the evolution of chemical diversity. , 2004, Natural product reports.

[28]  J. Smallheer,et al.  The race to an orally active Factor Xa inhibitor: recent advances. , 2004, Current opinion in drug discovery & development.

[29]  M. Gregory,et al.  Isolation and characterization of pre-rapamycin, the first macrocyclic intermediate in the biosynthesis of the immunosuppressant rapamycin by S. hygroscopicus. , 2004, Angewandte Chemie.

[30]  H. Kubinyi.  Drug research: myths, hype and reality , 2003, Nature Reviews Drug Discovery.

[31]  T. Nakata.  Total Synthesis of Macrolides , 2003 .

[32]  J. Staunton,et al.  Polyketide biosynthesis: a millennium review. , 2001, Natural product reports.

[33]  F. Lombardo,et al.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. , 2001, Advanced drug delivery reviews.

[34]  P. Leadlay,et al.  The biosynthetic gene cluster for the polyketide immunosuppressant rapamycin. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[35]  Shibo Jiang,et al.  HIV-1 inhibition by a peptide , 1993, Nature.

[36]  A. Nagel,et al.  Macrolide antibiotics. Chemistry, biology, and practice , 1985 .